Clinical Trial

Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)

Study acronym: A-SAB
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 10, 2023 (before its estimated June 20, 2024 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn evaluate the safety and efficacy of the addition of radiation therapy to all tumour lesions, to first line medical treatment with alectinib in non-small cell lung cancer harbouring ALK-rearrangements. The main aims of the trial are to evaluate: * if the treatment combination is safe * if the treatment combination can inhibit progression Participants who have responded to 1st line alectinib will be treated with consolidation radiation therapy to all remaining tumour lesions while continuing on alectinib until disease progression, unacceptable toxicity or another discontinuation criterion is met.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-02-01; most recent amendment 2023-10-06.
Status change: Not Yet Recruiting → Recruiting 2023-10-06
Trial Details
NCT Number NCT05724004
Lead Sponsor Karolinska University Hospital
Collaborators: Sahlgrenska University Hospital
Conditions Radiotherapy Side Effect, Non-small Cell Lung Cancer, ALK Gene Mutation
Enrollment 70 participants
Start Date 2023-10-05
Primary Completion 2024-06-20 (estimated)
Study Completion 2031-06-20 (estimated)
Updated on ClinicalTrials.gov 2023-10-10